Trump’s DOJ Blocks Pro-Life States’ Lawsuit Against Mail-Order Abortion Pills

The Justice Department just threw a roadblock in front of Republican-led states fighting to stop abortion pills from flooding across their borders through the mail—and pro-life advocates are furious.

In a Friday filing, the DOJ moved to shut down Missouri’s lawsuit challenging the FDA’s policy allowing mifepristone to be shipped directly to women in states where abortion is banned. The department wants the case delayed or dismissed entirely while the Trump administration conducts its own safety review.

But here’s the problem: That review was promised last year, and pro-life Americans are still waiting.

The Federal Government’s Preemption Play

The Justice Department’s argument boils down to federal supremacy. DOJ lawyers claim that allowing Missouri’s lawsuit to proceed would interfere with the FDA’s ongoing Risk Evaluation and Mitigation Strategy (REMS) review of mifepristone.

Missouri, Kansas, and Idaho aren’t asking for much. They want a judge to block the COVID-era policy that gutted common-sense regulations for dispensing abortion drugs. These states have every right to protect unborn life within their borders.

The DOJ filing dismisses these legitimate state concerns with bureaucratic double-speak, insisting states “remain free to make and enforce their pro-life policies” while simultaneously blocking their ability to do exactly that.

A Pattern of Delay and Deflection

This isn’t the first time the Trump administration has used procedural maneuvers to sideline pro-life states. A nearly identical filing in January sought to derail Louisiana’s attempt to stop the FDA’s mail-order abortion scheme.

The administration keeps pointing to the REMS review initiated by FDA Administrator Marty Makary and HHS Director Robert F. Kennedy Jr. as justification for inaction. But promises don’t save babies—policies do.

Pro-life lawmakers and advocates have grown increasingly impatient as abortion numbers climb in states with protective laws, fueled by an avalanche of pills shipped from out-of-state abortionists.

The Deadly Reality Behind the Bureaucracy

The data tells a stark story. Tens of thousands of abortions continue in states like Texas, where medication abortion is explicitly banned. These aren’t hypothetical violations—they’re real babies dying because federal policy enables abortion traffickers to operate with impunity.

Texas Attorney General Ken Paxton has attempted to hold these pill-pushing abortionists accountable, but states like New York have erected “shield laws” protecting them from prosecution. The federal government could intervene to support states enforcing their duly enacted laws. Instead, it’s choosing delay tactics.

Pro-Life Movement Demands Action

Susan B. Anthony Pro-Life America President Marjorie Dannenfelser didn’t mince words in her condemnation of Friday’s filing.

“The pro-life movement has very simple demands,” Dannenfelser stated. “There should be no place on the market for drugs meant to poison and kill innocent human beings—but at the very least, this administration can and should take them out of the mail.”

She’s absolutely right. This isn’t complicated policy analysis. During Trump’s first term, the administration didn’t allow abortion pills to flow freely through the postal service. Why the change now?

The Courts Versus the Bureaucrats

A Justice Department spokesman claimed the filing merely seeks to preserve FDA authority over drug policy rather than allowing federal courts to make those decisions. The spokesman cited a recent Supreme Court ruling recognizing the FDA’s role in evaluating drug safety data.

But that argument misses the point entirely. Pro-life states aren’t asking courts to second-guess FDA pharmacology. They’re asking courts to recognize that states have constitutional authority to protect unborn life within their borders—authority the Supreme Court explicitly returned to them when it overturned Roe v. Wade.

The federal government cannot simultaneously claim to support federalism on abortion while actively blocking states from enforcing their own laws.

Empty Reassurances

The Justice Department spokesman offered the standard talking points, claiming the department remains “committed to advancing President Trump’s pro-life agenda, including through dismissing criminal prosecutions and civil lawsuits against peaceful pro-life advocates targeted by the previous administration, and using the FACE Act to protect pro-life pregnancy centers.”

Those are welcome actions, but they don’t address the elephant in the room: Why is a Republican administration defending an FDA policy that enables abortion in states where voters and legislators have chosen to protect life?

What Needs to Happen

The solution is straightforward. The Trump administration should immediately reinstate the pre-COVID regulations for mifepristone distribution. Chemical abortion drugs should require in-person dispensing with appropriate medical oversight.

If the FDA insists on completing its REMS review first, fine—but set a hard deadline and commit to restricting mail-order abortion pills afterward if the review confirms the serious safety concerns documented by pro-life medical experts.

In the meantime, the Justice Department should be supporting pro-life states’ enforcement efforts, not obstructing them. Federal prosecutors should be investigating abortion traffickers who flagrantly violate state laws, not filing motions to delay lawsuits against federal agencies enabling those violations.

The Stakes Couldn’t Be Higher

Every day this policy remains in place, more unborn children die in states where their elected representatives voted to protect them. Every delay allows abortion activists to further entrench their mail-order pill distribution networks.

The pro-life movement delivered overwhelming support to President Trump in 2024 with clear expectations. Republican voters want action on mail-order abortion pills, not bureaucratic excuses and procedural delays.

The administration must decide: Will it stand with pro-life states fighting to enforce their laws, or will it hide behind FDA reviews and federal preemption arguments while babies continue to die?

The answer to that question will define this administration’s pro-life legacy.